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Abstract Despite the close structural similarity between the heptapeptide cores of the 
glycopeptide antibiotics teicoplanin and ristocetin, synthetically modified derivatives of their 
aglycons show significantly different antibacterial and antiviral properties.The teicoplanin 
aglycon derivatives with one exception proved to be potent antibacterials but they did not 
exhibit anti-influenza virus activity. In contrast, the aglycoristocetin derivatives generally 
showed high anti-influenza virus activity and possessed moderate antibacterial activity. A 
systematic structure-activity relationship study has been carried out on ristocetin and 
teicoplanin aglycon derivatives, to explore which structural differences are responsible for 
these markedly different biological activities. According to electronic circular dichroism and 
in silico conformational studies, it was found that the differences in anti-influenza virus 
activity are mainly determined by the conformation of the heptapeptide core of the antibiotics 
controlled by the presence or absence of chloro substituents. Knowledge of the bioactive 
conformation will help to design new analogues with improved anti-influenza virus activity. 
For the teicoplanin derivatives, it was shown that derivatization to improve the antiviral 
efficacy was accompanied by a significant decrease in antibacterial activity.  
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Several years ago, we started a project focussed on semisynthetic investigation of the 
aglycons of the glycopeptide antibiotics teicoplanin and ristocetin. Inspired by examples of 
the semisynthetic antibiotics telavancin [1], dalbavancin [2] and oritavancin [3], we initially 
introduced lipophilic, mainly aromatic, side chains into the ristocetin aglycon molecule [4]. 
Ristocetin is not applied in medical practice because of its blood platelet aggregating 
properties [5]. It is known that this side effect can be attributed to the presence of an L-
rhamnose moiety in the ristocetin molecule [6]. Therefore, by removing the sugars from 
ristocetin and reattaching them by click reaction, we obtained new antibacterials devoid of 
this platelet aggregating activity [7]. 
A decade ago, Preobrazhenskaya et al. reported on the anti-HIV (and other antiviral) 
activities of a series of semisynthetic glycopeptide antibiotics bearing preferably lipophilic 
side chains [8]. We therefore evaluated the antiviral activity of several of our ristocetin 
derivatives obtained from ristocetin aglycon 1, by the squaramide coupling reaction with 
various amines [9]. Some of the new squaramides exhibited pronounced activity against 
influenza A and B viruses. Among them, the 4-phenylbenzyl substituted derivative 2 proved 
to be the most potent compound, displaying strong and broad anti-influenza virus activity, 
[10] and possessing also a moderate antibacterial activity [4] (Figure 1). Detailed mechanistic 
studies demonstrated that 2 interferes with influenza virus replication by disturbing 
endocytotic uptake of the virus, resulting in its intracytoplasmic trapping prior to nuclear 
entry of the viral genome [10]. 
 
Figure 1. Structures of ristocetin aglycon 1; its N-terminally modified derivative 2 which has 
potent and broad-activity against influenza virus; teicoplanin aglycon 3; and teicoplanin 
pseudoaglycon 4. The main differences between the glycopeptide cores are highlighted in 
magenta. 
  
Teicoplanin and ristocetin have nearly the same cross-linked linear heptapeptide aglycon with 
only a few differences. Teicoplanin aglycon 3 has a free carboxylic group and also two chloro 
substituents on the aromatic rings. Ristocetin aglycon 1 is a methyl ester and contains no 
chloro substituents, but has a hydroxylic group in a benzylic position as well as a methyl 
substituent on one of its aromatic rings (Fig 1). Because of the structural similarities, we 
decided to perform several chemical transformations both on teicoplanin and ristocetin 















aglycon 1 could easily be achieved from ristocetin by the Boger’s HF-method [11], similar 
anhydrous hydrogen fluoride treatment of teicoplanin provided pseudoaglycon 4 with a 
remaining N-acetyl glucosamine residue, the removal of which required harsh conditions and 
proceeded with low yield. Therefore, besides installing lipophilic side chains to the N-
terminal group of aglycoristocetin, we made similar transformations to teicoplanin 
pseudoaglycon [12-15]. Surprisingly, despite the close structural resemblance, significantly 
different antiviral properties were found for the two series of semisynthetic antibiotics. The 
teicoplanin derivatives did not exhibit anti-influenza virus activity, but most of them proved 
to be very potent antibacterials with outstanding activities against multidrug-resistant bacteria. 
In contrast, the aglycoristocetin derivatives generally showed moderate antibacterial activity, 
but possessed high anti-influenza virus activity. 
In the present work, we report on a systematic structure – biological activity relationship 
study of aglycon derivatives carrying the same 4-phenylbenzyl squaramide moiety as 
compound 2. In order to explore or define the structural requirements of the glycopeptide core 
for the antiviral activity, synthesis and biological evaluation of teicoplanin aglycon and 
pseudoaglycon derivatives were undertaken using compound 2 as the lead compound. Hence, 
the easily available teicoplanin pseudoaglycon 4 was modified in successive synthetic steps, 
involving deglycosylation, methyl ester formation and didechlorination. In this way, we 
wanted to increase the structural resemblance to the ristocetin aglycon derivative 2, and study 
how these modifications affect the antibacterial and anti-influenza virus activities. NMR, CD 
and computational studies were also performed to provide a rationale for the observed 
structure-activity trends. 
 
Results and Discussion 
Synthesis and biological evaluation 
First, the 4-phenylbenzyl squaramide moiety was introduced to the N-terminus of the peptide 
core of teicoplanin ψ-aglycon 4 by using the two-step Tietze conjugation method [16]. 
Condensation of 4 and the squaric acid derivative 5 resulted in 6, reaction of which with 4-
phenylbenzylamine afforded compound 8 in 41% yield over two steps. As ristocetin aglycon 
exists in methyl ester form, the free C-terminus of 4 was esterified with MeOH, and the 
obtained methyl ester 9 was transformed, through the squaric acid 10, to another squaramide 
derivative, compound 11 (Scheme 1). The antibacterial activities were excellent for the 
pseudoaglycone methyl ester 9  and somewhat lower for its squarate 10 (Table 1). The  ester 















strains, while its carboxylic acid analog 8 possessed no activity against enterococci having 
vanA resistance genes and exhibited weak activity against enterococci with vanB resistance 
genes.  Compounds 8, 9, 10 and 11 were completely inactive against influenza virus (Table 
2). 
 
Scheme 1. Synthesis of 8 and 11 as teicoplanin-pseudoaglycon-counterparts of compound 2 
 
In order to increase the similarity of the squaramides obtained from teicoplanin to 2, the N-
acetyl-D-glucosamine moiety of 4 was removed hydrolytically, and aglycon 3 was 
transformed to the free carboxylate 13 and methyl ester 15, according to the squaramide 
method described above (Scheme 2). Carboxylic acid 13 proved to be a good antibacterial but 
its methyl ester 15 had no activity. Both of them were inactive against influenza virus. The 
structural differences between 2 and 15 are: a methyl attached to an aromatic ring and a 
hydroxyl group in the benzylic position of 2, and two aromatic chloro substituents in 15.  
 
Scheme 2. Transformation of teicoplanin pseudoaglycon 4 into the N-terminally modified teicoplanin aglycon 
13 and its methyl ester 15 
 
Table 1. Antibacterial activity of the synthesized compounds  
 
Finally, compound 18, the closest analog of 2 available from 4, was prepared via a sequence 
of reactions (Scheme 3). First, replacement of the chloro substituents by hydrogens was 
accomplished by catalytic hydrogenation under 4 atm pressure to give 16. Subsequent 
hydrolytic removal of N-acetylglucosamine followed by esterification at the C-terminus 
resulted in 17 which was equipped with the 4-phenylbenzyl squaramide moiety to provide 18. 
 
 
Scheme 3. Transformation of teicoplanin pseudoaglycon 4 into the N-terminally modified didechlorinated 
teicoplanin aglycon methyl ester 18 via didechlorinated teicoplanin aglycon methyl ester 17 
 
 
Table 2. Activity in influenza virus-infected MDCKa cells 
 
Compound 18 exhibited modest antibacterial activity, but displayed high anti-influenza virus 
activity against both the A/H1N1 and A/H3N2 subtype. It was inactive, however, against 
influenza B virus. 
Summarizing the synthetic results, starting from teicoplanin pseudoaglycon 4, we changed its 















derivative 2 which has strong anti-influenza virus activity. The end point of these 
transformations was compound 18, the structure of which shows the closest similarity to 2. 
Biological evaluation of the novel derivatives showed that removal of the chloro substituents 
significantly decreases, if not eliminates, the antibacterial activity. The other synthetic 
modifications of 4 (i.e. other than didechlorination) only slightly affected the antibacterial 
activity.  
On the other hand, the antiviral evaluations revealed that only the ristocetin derivative 2 and 
its closest analog 18 possess anti-influenza virus activity. Presence of  the chloro substituents 
proved to be detrimental for the influenza virus inhibitory effect. To explain this finding, we 
decided to study how these small structural differences can influence the conformation or 
charge distribution of these aglycon derivatives. Since lipophilicity can be an important 
contributing factor to biological activity, we performed logP calculations for compounds 2, 15 
and 18 (Table 3.) It can be seen that compounds 2 and 18, which possess comparable anti-
influenza virus activity, have almost identical logP values. The inactive derivative 15 is more 
lipophilic with a logP value that is half order of magnitude higher. This suggests that for this 
group of glycopeptide derivatives, there is an optimum lipophilicity to obtain inhibition of 
influenza virus.  
 
 
Table 3. Calculated logP values for the 4-phenylbenzyl squaramide-derivatives 2, 15 and 18 
 
 
ECD, NMR and Computational studies 
For the sake of simplicity, compounds ristocetin aglycon 1, teicoplanin aglycon methyl ester 
14, and didechloro teicoplanin aglycon methyl ester 17 were chosen for the instrumental and 
theoretical studies (Fig 2).  
 
Figure 2. Structure and numbering for ristocetin aglycon 1, teicoplanin aglycon methyl ester 14, and 
didechloro teicoplanin aglycon methyl ester 17 
 
Since electronic circular dichroism (ECD) spectra usually are very informative for the 
stereostructure, ECD spectra of the three aglycons were recorded in water. The ECD spectra 
of aglycoristocetin 1 and didechloro teicoplanin aglycon methyl ester 17 were nearly identical 
with negative Cotton effects (CE) at 244 and 288 nm accompanied by a positive CE at 202 


















Figure 3. ECD spectra of ristocetin aglycon 1, teicoplanin aglycon methyl ester 14, and didechloro 
teicoplanin aglycon methyl ester 17, recorded in water 
 
The similar ECD curves of 1 and 17 prove that they adopt a similar conformation regarding 
the orientation of amide and aryl chromophores. In contrast, teicoplanin aglycon methyl ester 
14 having two additional chloro substituents at the aryl rings showed a markedly different 
ECD spectrum. This is reflected in an intense positive CE at 223 nm and a negative one at 208 
nm, which were missing from the ECD spectra of 1 and 17. The two negative high-
wavelength CEs also appeared in the ECD of 14, but their shapes, relative intensities and 
wavelength were different. This clearly indicates that in the presence of the two chlorine 
atoms, the preferred conformation or conformational ensemble of the teicoplanin aglycon 14 
significantly differs from the conformation of aglycoristocetin 1, and upon removal of the 
chlorine atoms, compound 17 adopts a conformation very similar to that of 1. 
 
Conformational analysis at MM level 
 
Clustering of the low-energy 42 kJ/mol part of the GAFF (General Amber Force Field) 
[17,18] optimized high-temperature in vacuo molecular dynamics trajectory resulted 207, 204 
and 145 clusters for 1, 14 and 17, respectively. ESP (Merz–Kollman) charges [19,20] were 
computed for the lowest-energy conformers of the three aglycons at HF/6-31G(d) level (see 
Fig. S1 in the SI). Basically, there were only small differences in the charge distribution of the 
three aglycons, indicating that the experimentally observed differences can not be mainly 
from the result of electronic background.  
 
Figure 4. Comparison of the lowest-energy MM conformers of a) ristocetin aglycon 1 (blue) 
and didechloro teicoplanin aglycon methyl ester 17 (red), b) ristocetin aglycon 1 (blue) and 
teicoplanin aglycon methyl ester 14 (red) 
 
Comparing the global minima obtained at GAFF level in vacuo by superimposing the lowest-
energy conformers (Fig 4), structures of 1 and 17 were highly similar, while there were minor 
differences between 1 and 14 mostly in residues 5 and 7 (numbering is given in Fig. 2). 
Comparison of all low-level conformers of the three aglycons yielded similar results than the 
global minima, i.e. 1 and 17 are rather similar and differ from 14, and the difference is mainly 















varies within these 2 residues in the global minima vs. in the whole considered low-energy 
regions. (See Figs S2 and S3 in the SI) 
 
Reoptimization at DFT level with solvent model 
All low-energy conformers resulted by the above mentioned clustering were reoptimized at 
B3LYP/6-31G level with PCM solvent model for water. In line with the MM results, the 
conformers of DFT global minima of 1 and 17 were very similar, while there were minor 
differences from 14 mostly in residues 1 and 3 (see Fig. 5). These latter results are in 
agreement with previous observations known from the literature, i.e. residues 5 and 7 seemed 
to be rather rigid in normal temperature dynamics simulations with explicit water, while 1 and 
3 showed a certain level of flexibility [21]. It is interesting to note that global minima of 1 and 
17 obtained after DFT reoptimization exhibit cis bond between residues 5 and 7 which is well 
known in the literature [22]. On the other hand, in the case of 14 the lowest-energy conformer 
with the same cis bond is only the 6th lowest one after the same reoptimization. Although DFT 
levels can have a certain error rate and the basic set applied here is rather small because of the 
size of the molecules, it is very likely that the overall population of trans isomers in 14 is 
much higher than for the two other aglycons. 
 
Figure 5. Comparison of the lowest-energy B3LYP/6-31G PCM/H2O conformers of a) 
ristocetin aglycon 1 (blue) and didechloro teicoplanin aglycon methyl ester 17 (red), b) 
ristocetin aglycon 1 (blue) and teicoplanin aglycon methyl ester 14 (red) 
 
In order to support the theoretical calculations, NOESY experiments were carried out for 
interproton distance determinations. Because of the limited dynamic range of the NOE 
spectra, distances longer than 3.3 Å could not be obtained. In Tables 6-8, NMR NOE 
distances are compared to interproton distances from DFT (B3LYP/6-31G, PCM/H2O) 
reoptimized MD calculations, and the lowest energy conformer was arbitrarily chosen for 
comparison.The qualitative agreement is generally acceptable, however in a few cases the 
NMR experimental distances underestimate the distances from MD calculations. 
It is worth mentioning that the NMR studies were done in DMSO while the ECD spectra were 
recorded in water. In DMSO ECD can be measured only down to ca. 230 nm while in water 
we could get good spectra down to 190 nm. Since there are main differences in the ECD 















for ECD measurements. Furthermore, conformers in DMSO are hard to compute because of 
the strong complex-formation feature of this solvent [23]. 
 
Computed ECD spectra 
ECD spectra of the DFT reoptimized global minima of 14, 1 and 17, and the lowest-energy 
cis isomer of 14 were computed at B3LYP/6-31G and B3LYP/6-31G(d) levels of theory with 
PCM solvent model for water as well as at the semiempirical ZINDO level in vacuo (since 
ZINDO can not handle chlorine it was changed to fluorine in 14 at this level). To check the 
influence of the halogen on the ECD spectra, Cl (or F) was replaced by hydrogen in 14 (14-H) 
and halogen was introduced in the corresponding positions of 17 (17-Cl / 17-F). Addition or 
removal of halogens without reoptimizations of the original geometries did not induce a 
remarkable change in the computed ECD spectra, which suggested that the differences of the 
experimental ECD curves should derive from the different conformational ensemble of the 
studied derivatives (Fig 6). Thus, the difference of the ECD curves cannot be attributed 
exclusively to the presence of halogen atoms, which may theoretically change the direction of 
the electric transition moments of the interacting aryl chromophores. 
 
Figure 6. ZINDO computed ECD spectra of 14-F vs. 14-H obtained without reoptimization of the 
lowest-energy conformer of 14 (left) and those of 17 and 17-F obtained without reoptimization of the 
lowest-energy conformer of 17 (right) 
 
Computed spectra of 1 and 17 were rather similar in accordance with the experimental data, 
while those of 14 were markedly different (see Figs S4 – S6 in the SI). Although the 
computed ECD spectra reproduced the major ECD transitions, they did not allow an 
unambiguous verification of the conformational distribution. 
 
Summary 
Based on this systematic structure – anti-influenza virus activity study of ristocetin and 
teicoplanin aglycone derivatives, we proved that the presence of a lipophilic side chain is 
crucial for the antiviral activity. Moreover, according to our CD measurements and in silico 
studies, the conformation (and not the electron distribution) determined mostly by the 
presence or absence of the chloro substituents is also a determinant factor of bioactivity. 
Regarding influenza virus, the mode of action of 2 is related to disruption of endocytotic 















remains to be elucidated, we here defined the optimal conformation of the glycopeptide to 
achieve tight binding to its target molecule. In a next step, we hope to use these findings to 




Materials and Methods. Unless otherwise stated the starting materials and solvents were 
purchased from commercial sources (Sigma-Aldrich or Fluka) and used as received. All 
solvents were distilled prior to use. CH2Cl2 was distilled from P2O5
 
and stored over 4 Å 
molecular sieves. Triethylamine was distilled from KOH before use. 1H and 13C NMR spectra 
were recorded at 500.13 / 125.76 MHz frequencies, respectively, with a Bruker AVANCE II-
500 spectrometer at 300 K, using DMSO-d6, as solvent and TMS (tetramethylsilane) as 
internal standard. 1H 90o pulses were typically 11 us, while the 13C 90o pulse was 15 us. 
Signal assignments were aided by 2D HSQC, COSY, TOCSY (15 and 60 ms mixing times) 
and HMBC (60 ms mixing time) experiments. For interproton distance determinations 2D 
NOESY experiments equipped with an extra 6 ms spin-echo were run using 200 ms mixing 
time. NOE distance estimations were obtained by the internal reference method, using the 1.8 
Å geminal proton (z2) or ortho protons in aromatic rings as reference distance. NMR spectra 
were processed with Bruker Topspin 3.0 software. CD spectra were recorded on a JASCO J-
810 spectropolarimeter using water as solvent. Mass spectra were recorded with a Bruker 
Biflex-III MALDI TOF mass spectrometer. For column chromatography Merck silica gel 
(Kieselgel 60), 0.063-0.20 0 mm (70-230 mesh) was used. Thin layer chromatography (TLC) 
was performed on Kieselgel 60 F254
 
(Merck), using UV light and Pauly’s reagent for 
visualization of the spots. Evaporations were carried out under diminished pressure at 35-45 
°C (bath temperature). 
 
Computational section 
The three aglycons were constructed utilizing the NMR refined structure of vancomycin 
derivative 1GAC from the PDB database. The molecular dynamics simulations (100 ns, 1200 
K constant temperature, 1 fs time step) and the preliminary geometry optimizations using the 
suitably developed GAFF empirical force field on the equidistantly saved 200,000 trajectory 
snapshot geometries were carried out by means of the AMBER molecular dynamics 
simulation package.[24, 25] The first 42 kJ part of the optimized geometries were clustered 















reoptimization. Geometry optimizations [B3LYP/6-31G with PCM solvent model for water] 
and ECD calculations were performed with Gaussian 09 [27] at B3LYP/6-31G, B3LYP/6-
31G(d) and ZINDO levels. ECD spectra were generated as the sum of Gaussians [28] with 
2100 and 900 cm−1 half-height width (corresponding to 12 and 5 nm at 240 nm, respectively) 
using dipole-velocity computed rotational strengths. The Chimera [29] and GaussView [30] 
software packages were used for visualization of the results. 
The logP values were calculated based on the model proposed by Tetko et al. [31, 32] using 
the ALOGPS 2.1 web server http://www.vcclab.org/lab/alogps/ (accessed: 2015/02/04). 
 
Synthesis 
General method for preparation of the squaric acid derivatives 6, 10, and 12. 
To a solution of amine (0.1 mmol) in 10 mL of methanol triethylamine was added to adjust 
pH level between 7 and 7.5. After addition of squaric acid 5 (0.13 mmol), the solution was 
stirred for 20 hours at room temperature, and was evaporated in vacuum. The crude products 
were purified by flash column chromatography (10: toluene – methanol = 1 : 1; 12: toluene – 
methanol – acetic acid = 5 : 5 : 0.01; the other products were used on as crude materials in the 
following steps) to yield the appropiate squaric acid derivatives (10: 52%; 12: 71% over two 
steps). 
10: MALDI-TOF MS [M+Na+]: 1547.25 Da; Calcd for C72H62Cl2N8O26Na+: 1547.30. 
12: MALDI-TOF MS [M+Na+]: 1332.20 Da; Calcd for C63H49Cl2N7O21Na+: 1332.23. 
 
General method for preparation of the 4-phenylbenzyl derivatives 8, 11, 13, 15 and 18.  
To a solution of a squaric acid derivative (0.05 mmol) in 5 mL of methanol triethylamine was 
added to adjust pH level between 8 and 9. After addition of 4-phenylbenzylamine 7 (0.075 
mmol), the solution was stirred for 20 hours at room temperature, and was evaporated in 
vacuum. The crude products were purified by flash column chromatography (11: toluene – 
methanol – acetic acid = 5 : 5 : 0.01; 13: toluene – methanol – acetic acid = 7 : 3 : 0.01; 15: 
DCM – methanol = 8 : 2; 18: toluene – methanol = 8 : 2; in the case of 8, column 
chromatography was not necessary, the precipitated product was washed with cold methanol 
and dry ether) to yield the appropiate 4-phenylbenzyl derivatives (8: 63%; 11: 57%; 13: 64%; 
15: 28% over two steps; 18: 21% over two steps). 
8: MALDI-TOF MS [M+Na+]: 1684.43 Da; Calcd for C83H69Cl2N9O25Na+: 1684.37. 
11: MALDI-TOF MS [M+Na+]: 1698.49 Da; Calcd for C84H71Cl2N9O25Na+: 1698.38. 















15: MALDI-TOF MS [M+Na+]: 1497.23 Da; Calcd for C67H60Cl2N8O23Na+: 1497.32. 
18: MALDI-TOF MS [M+Na+]: 1429.38 Da; Calcd for C76H62N8O20Na+: 1429.40. 
 
General method for preparation of the methyl esters 9, 14, and 17.  
0.1 mmol of the free acid was dissolved in a mixture of 1.25 M HCl solution in methanol and 
methanol (1:10, 20 mL). The mixture was stirred under reflux for 1.5 hour and was 
evaporated in vacuum. The crude products were purified by flash column chromatography 
(toluene – methanol – acetic acid = 6 : 4 : 0.01) to yield the appropiate methyl ester products 
(9: 69%; 14: 45% over two steps; 17: 64 % over two steps). 
9: MALDI-TOF MS [M+Na+]: 1437.55 Da; Calcd for C67H60Cl2N8O23Na+: 1437.30. 
14: MALDI-TOF MS [M+Na+]: 1234.22 Da; Calcd for C59H47Cl2N7O18Na+: 1234.22. 
17: MALDI-TOF MS [M+Na+]: 1166.50 Da; Calcd for C59H49N7O18Na+: 1166.30. 
 
Cleavage of the N-acetyl-D-glucosamine moiety from pseudo teicoplanin aglycon derivatives 
4 and 16. 
The solution of the N-acetyl-D-glucosamine derivative (0.2 mmol) in 5 mL of 90% 
trifluoroacetic acid was stirred for 8 hour at 80 °C. The cooled mixture was poured into 100 
mL of cold ether, the product was filtered out and dried. The crude products were used for 
further conversions. 
 
Dechlorination process of 4. 
To the solution of teicoplanin pseudoaglycon 4 (0.1 mmol) in 7 mL of methanol and 3 mL of 
0,04 M HCl solution 100 mg of 10 % Pd/C catalyst was added and the mixture was kept first 
under 1 atm pressure for 4 hours, then overnight under 5 atm with additional 200 mg of Pd/C 
catalyst in 4 mL of water. The reaction mixture was filtered through Cetite® and was 
evaporated in vacuum to yield compound 16 (72%). 





Figure 7. Numbering atoms in teicoplanin derivatives  
 

















Table 5. 13C NMR data (chemical shifts in ppm) 
 
 
Table 6. Measured and calculated distances of the proton pairs giving NOE in compound 1  
(Interproton distances in Å). The lowest energy conformer was arbitrarily chosen for 
comparison. 
 
Table 7. Measured and calculated distances of the proton pairs giving NOE in compound 14  
(Interproton distances in Å). The lowest energy conformer was arbitrarily chosen for 
comparison. 
 
Table 8. Measured and calculated distances of the proton pairs giving NOE in compound 17  
(Interproton distances in Å). The lowest energy conformer was arbitrarily chosen for 
comparison. 
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Figure 1. Structures of ristocetin aglycon 1; its N-terminally modified derivative 2 which has 
potent and broad-activity against influenza virus; teicoplanin aglycon 3; and teicoplanin 
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10 R =CH3 (52%)
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11 R = CH3 (57%)














































































14 (45% over two steps)
90 % TFA















13 R = H (64% from 12)
































12 (71% over two steps)
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MeOH / DMF, Et3N
pH > 7
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Scheme 2. Transformation of teicoplanin pseudoaglycon 4 into the N-terminally modified teicoplanin aglycon 
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18 (21% over two steps)
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Scheme 3. Transformation of teicoplanin pseudoaglycon 4 into the N-terminally modified didechlorinated 

















Figure 2. Structure and numbering for ristocetin aglycon 1, teicoplanin aglycon methyl ester 14, and 






Figure 3. ECD spectra of ristocetin aglycon 1, teicoplanin aglycon methyl ester 14, and didechloro 

















Figure 4. Comparison of the lowest-energy MM conformers of a) ristocetin aglycon 1 (blue) 
and didechloro teicoplanin aglycon methyl ester 17 (red), b) ristocetin aglycon 1 (blue) and 
















Figure 5. Comparison of the lowest-energy B3LYP/6-31G PCM/H2O conformers of a) 
ristocetin aglycon 1 (blue) and didechloro teicoplanin aglycon methyl ester 17 (red), b) 


















Figure 6. ZINDO computed ECD spectra of 14-F vs. 14-H obtained without reoptimization of the 
lowest-energy conformer of 14 (left) and those of 17 and 17-F obtained without reoptimization of the 

























Table 1. Antibacterial activity of the synthesized compounds  
Strains 
MIC (µg/mL) 
Teicoplanin Ristocetin 2 8 9 10 11 12 13 15 18 
Bacillus subtilis ATCC 6633 0.5 16 2 4 0.5 8 8 16 8 256 16 
Staphylococcus aureus MSSA ATCC 29213 0.5 128 1 1 0.5 2 2 1 2 128 8 
Staphylococcus aureus MRSA ATCC 33591 0.5 32 8 4 1 8 0.5 2 2 256 32 
Staphylococcus epidermidis mecA 16 128 2 1 0.5 8 0.5 2 2 32 8 
Staphylococcus epidermidis biofilm ATCC 35984 4 2 2 1 0.5 4 0.5 2 0.5 256 32 
Enterococcus faecalis ATCC 29212 1 4 1 4 2 2 0.5 4 1 64 4 
Enterococcus faecalis 15376 vanA+ 256 16 n.d. 256 0.5 0.5 0.5 2 1 128 16 
Enterococcus faecalis ATCC 51299 vanB+ 0.5 256 8 8 1 4 0.5 8 8 256 4 
MIC: Minimum Inhibitory Concentration; ATCC: American Type Culture Collection; vanA+: vanA gene positive; MSSA: Methicillin 
Sensitive Staphylococcus; mecA: mecA gene expression in Staphylococcus; vanB+: vanB gene positive; MRSA: Methicillin Resistant 

















Table 2. Activity in influenza virus-infected MDCKa cells 
 
Compound 








MCC  CC50 CPE MTS CPE MTS CPE MTS 
 (µM) 
Ristocetin aglycon (1) 81 44 n.d. n.d. 4.6 2.5 5.1 5.4 
Teicoplanin ψ-aglycon (4) ≥ 100 > 100 23 43 17 34 > 100 > 100 
2 20 39 0.15 0.21 0.15 ≤ 0.42 0.84 1.0 
3 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
8 0.8 6.5 > 100 > 100 > 100 > 100 > 100 > 100 
9 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
10 100 > 100 > 100 > 100 > 100 > 100 > 100 > 100 
11 20 58 > 100 > 100 > 100 > 100 > 100 > 100 
12 100 49 > 100 > 100 > 100 > 100 > 100 > 100 
13 20 11 > 100 > 100 > 100 > 100 > 100 > 100 
15 4 7.6 > 100 > 100 > 100 > 100 > 100 > 100 
18 16 20 0.67 0.58 0.52 0.70 >100 >100 
Oseltamivir carboxylate > 100 > 100 2.0 2.9 4.0 2.3 20 15 
Ribavirin > 100 > 100 9.0 8.9 12 12 7.0 3.4 
Amantadine > 500 > 500 224 453 2.0 1.8 > 500 > 500 
Rimantadine > 500 > 500 4.0 15 4.0 1.1 > 500 > 500 
aMDCK, Madin-Darby canine kidney cells. Data shown represent the means of 2 to 5 independent tests. 
bCytotoxicity was expressed as the minimum cytotoxic concentration (MCC; compound concentration producing minimal changes in cell 
morphology, as estimated by microscopy) or the 50% cytotoxic concentration (CC50; estimated by the MTS cell viability assay). 
cAntiviral activity was expressed as the EC50 defined as the compound concentration producing 50% inhibition of virus replication, as 
estimated by microscopic scoring of the cytopathic effect (CPE) or by measuring cell viability in the formazan-based MTS assay. 




Table 3. Calculated logP values for the 4-phenylbenzyl squaramide-derivatives 2, 15 and 18 
 
Compound 2 15 18 

















Table 4. 1H NMR data (chemical shifts in ppm) 
 
 1* 3 4 8 13 14 17 18 
5b 7.12 7.123 7.059 7.476a  7.095 7.12  
2b 7.837 7.22 7.212 7.166  7.179 7.062  
2f  7.646 7.652   7.629 7.716  
6c     
 
 6.725  
6f 7.539 7.466 7.256 7.246 7.42 7.456 7.482 7.46 
6b 7.474 7.8 7.873 7.856 7.81 7.79 7.557 7.79 
2c       7.122  
5f  6.72 6.636 6.654 6.64 6.67 6.684 6.64 
1f  7.125 7.194  7.09 7.038 7.113  
2e  7.224 7.169 7.15a 7.18 7.134 7.009  
6e  7.234 7.26 7.138 7.20 7.216 7.076  
1e  6.936 6.986 6.93 6.93 6.905 7.023 6.93 
1b  6.682 6.736 6.752 6.74 6.698 6.816 6.74 
5e  6.67 6.625 6.656 6.63 6.681 6.685 6.56 
3b 6.414 6.359 6.342 6.319 6.32 6.313 6.313 6.30 
4b 5.647 5.568 5.528 5.56 5.52 5.516 5.593 5.59 
7f 6.075 6.292 6.38 6.308  6.05 6.075 6.03 
3d  6.34 6.3 6.33 6.33 6.32 6.358 6.32 
4f 5.294 5.147 5.081 5.11 5.13 5.128 5.323 5.31 
3f 6.452 6.4 6.378 6.455 6.44 6.46 6.48 6.34 
7d 6.419 6.4 6.377 6.308 6.28 6.434 6.446 6.29 
Z6 5.126 5.117 5.295 5.376 5.16 5.09 5.115 5.11 
X6 4.155 4.14 4.151 4.173  4.136 4.164  
X3 5.249 5.358 5.353 5.343  5.325 5.297 5.31 
X1 4.63 4.587 4.998 6.03a  4.721 4.787  
X7 4.505 4.459 4.424 4.292  4.508 4.505 3.78 
X4 5.627 5.631 5.65 5.618  5.627 5.575 5.56 
X2 5.115 5.02 4.932 5.005  4.996 4.906 4.97 
X5 4.397 4.384 4.286 4.365  4.354 4.417 4.44 
Z2 5.154 2.869/3.321a 3.338/2.815a 3.25/2.86a  2.82/3.26a 2.86/3.26a 3.23/2.86a 
Me 3.689     3.689 3.687  
         
G-1   4.339 4.369     
G-2   3.362 3.528     
G-3   3.434 3.384     
G-4   3.078 3.226     















G-6   3.49/3.69a 3.617     
CH3 
(NHAc) 
  1.889 1.765     
         
N-CH2 
sidechain 
       4.77 
PhBn    7.466 7.46   7.46 
PhBn    7.427 7.42   7.43 
PhBn    7.371 7.36   7.36 
PhBn    7.677 7.65   7.66 





Table 5. 13C NMR data (chemical shifts in ppm) 
 
 1* 3 4 8 13 14 17 18 
y1  173.21 174.18 174.17  172.19 173.21  
y7  172.25 171.32 171.15  170.48 172.2  
y4  170.05 171.14 170.9  169.86 170.5  
y2  169.06 169.93 170.37  169.8 169.86  
y5  169.06 169.89 169.98  168.87 169.82  
y3  168.01 169.07 169.04  168.56 168.77  
y6  167.35 167.15 168.86  166.71 168.72  
3c  158.44 159.38 159.42  159.12 159.07  
7e  157.3 158.73 158.52  158.15 157.93  
3e  157.1 158 157.81  158 157.78  
7c  156.35 157.19 1569  157.41 157.17  
5d  155.4 156.39 156.4  156.05 155.91  
2d  150.68 151.74 151.76  151.13 155.13  
6d  148.63 150.21 150.07  149.3 155.03  
4c  147.61 149.35 148.98  148.2 150.04  
4e  147.5 148.74 148.71  147.98 149.75  
1d  146.83 148.44 148.43  147.81 147.84  
6a  142.04 143.15 143.35  142.52 142.13  
1c  141.47 141.66 141.71  141.96 141.31  
3a  140.7 139.18 139.43  141.54 139.9  
7a  136.14 137.76 138.75  135.96 135.82  
5b 136.12 135.53 136.58 136.75a  136.3 136.35  
2a  135.42 136.3 136.46  135.77 135.29  















1a  131.48 128.19 128.23  128.36 128.17  
2b 128.63 130.9 131.85 131.92  131.21 131.32  
2f  129.87 131.18 131.24  131.13 131.9  
4a  127.61 128.82 128.76  127.78 126.48  
6c  127.51 127.54 126.36 
 
127.78 121.86  
6f 127.1 127.22 129 128.36 127.61 127.78 128.61 127.03 
6b 128.67 127.16 129.51 129.43 127.81 127.81 127.14 127.30 
2c  126.11 126.76   126.63 124.11  
5a  125.83 126.46   126.32   
5f  125.66 126.57 126.04 125.49 126.26 126.21 125.79 
1f  124.89 125.73 125.66 125.83 125.27 125.09  
2e  124.55 127.02 124.14a 125.08 125.13 123.2  
6e  123.08 124.22 123.3 123.44 123.72 121.14  
5c  121.13 122.44 122.71  121.6 121.39  
1e  118.25 119.34 119.69 118.99 118.54 118.45 119.10 
7b  117.69 118.63 118.66  118.15 118.18  
1b  117.45 119.91 119.07 119.06 118.5 118.7 118.68 
5e  116.52 117.52 117.33 116.74 117.13 117.04 117.45 
3b 109.86 110.01 110.86 110.95 110.31 110.39 110.21 110.21 
4b 107.14 107.18 108.6 108.52 10764 107.66 107.6 107.34 
7f 105.77 105.94 105.84 105.91  105.68 105.83 105.15 
3d  104.87 107.1 107.84 105.18 105.28 105.43 105.01 
4f 106.05 104.3 105.43 105.91 104.77 104.84 106.37 106.24 
3f 103.9 102.66 104.35 104.35 103.47 103.78 103.99 103.51 
7d 103.07 102.66 103.16 102.78 102.11 103.33 103.22 102.96 
Z6 72.3 71.4 76.78 76.31 71.68 71.96 72.35 72.20 
X6 62.48 61.63 61.83 61.53 62.25 62.2 62.46  
X3 58.43 57.94 58.98 59.08 58.76 58.74 58.68 58.66 
X1 58.51 57.92 56.73 59.46a  57.87 57.72  
X7 56.98 56.63 58.16 59.91 59.72 57 56.95 59.07 
X4 55.03 54.84 55.59 55.23 55.14 55.09 55.07 54.97 
X2 60.58 54.27 55.98 55.54 55.35 54.93 55.47 55.38 
X5 54.04 53.53 54.64 54.22 53.98 54.08 54.02 53.74 
Z2 71.94 36.69 37.25 36.95 37.02 37.51 37.62 37.33 
Me      52.26 52.28  
         
G-1   99.95 99.48     
G-2   56.98 56.26     
G-3   73.98 74.14     















G-5   77.71 77.73     
G-6   62.09 61.73     
2NH-CO, 
G 
  170.53      
CH3 
(NHAc) 
  24.03 24.12     
         
C=O (SA)    183.75 183.36    
C=O (SA)    183.34 182.97    
SA    167.19     
SA    166.69     
N-CH2 
sidechain 
    46.87   46.90 
PhBn    140.32     
PhBn    129.8 129.32   129.21 
PhBn    129.06 128.56   128.53 
PhBn    127.91 127.81   127.85 
PhBn    127.53 127.20   127.16 




Table 6. Measured and calculated distances of the proton pairs giving NOE in compound 1  











1b-3b 1.21E+008 2.6 2.5 
1f-1e 1.70E+008 2.5 2.5 
2b-2c 5.68E+007 3.0 2.5 
3b-x3 1.05E+008 2.7 3.8 
4f-x5 3.62E+007 3.2 3.4 
5b-x5 1.35E+008 2.6 2.3 
5b-x6 1.04E+008 2.7 2.7 
    
6b-w6 2.98E+007 3.3 2.8 
6f-x6 3.62E+007 3.2 2.6 
6f-z6 8.58E+007 2.8 2.5 
    















w7-5b 8.90E+007 2.8 2.2 
w7-x5 3.07E+007 3.3 3.6 
w7-x6 6.90E+007 2.9 2.3 
w7-z6 4.09E+007 3.2 3.5 
x5-x6 1.32E+008 2.6 2.1 




Table 7. Measured and calculated distances of the proton pairs giving NOE in compound 14  




Integrations of   





1b-3b 2.25E+07 2.0 2.5 
1b-x1 3.14E+06 2.7 3.7 
1f-1e 2.37E+07 2.0 2.5 
1f-x1 7.94E+06 2.3 2.4 
2b-z2a 6.59E+06 2.4 3.6 
2b-z2b 2.19E+07 2.0 2.4 
2f-2e 1.69E+07 2.0 2.5 
2f-x1 1.95E+06 3.0 3.9 
2f-z2 7.84E+06 2.3 2.6 
3f-x3 2.10E+07 2.0 4.6 
4b-4f 3.03E+06 2.8 4.3 
4b-x4 3.77E+06 2.7 3.3 
4f-x5 1.09E+07 2.2 4 
5b-x5 3.51E+07 1.8 2.6 
5b-x6 2.68E+07 2.0 3.8 
5b-z6 3.39E+06 2.7 6.1 
6b-5b 3.44E+06 2.7 5.4 
6b-x5 6.57E+06 2.4 4.9 
6b-x6 1.33E+07 2.2 2.2 
6b-z6 3.14E+07 1.9 3.1 
6f-6e 2.10E+07 2.0 2.5 
6f-w6 8.51E+06 2.3 3.9 
7f-Me 5.81E+06 2.5 3.5 
7f-w7 2.00E+06 3.0 3,5 















w5-5f 4.16E+06 2.6 3.2 
w5-x4 2.20E+07 2.0 3.5 
w5-x5 4.33E+06 2.6 2.2 
w7-b5 2.07E+07 2.0 2.6 
w7-b6 2.92E+06 2.8 4.5 
w7-x5 5.85E+06 2.5 4.5 
w7-x6 1.86E+07 2.0 2.4 
w7-x7 5.75E+06 2.5 2.9 
w7-z6 9.46E+06 2.3 4.2 
x2-z2 1.03E+07 2.2 2.5 
x2-z2 1.28E+07 2.2 2.3 
x5-x6 4.00E+07 1.8 4.5 
z2a-z2b 3.82E+07 1.8 1.8 
z6-x5 4.42E+06 2.6 6.6 




Table 8. Measured and calculated distances of the proton pairs giving NOE in compound 17  










1b-3b 4.25E+007 1.8 2.5 
1b- x1 3.94E+006 2.7 3.8 
1f- x1 7.48E+006 2.4 2.4 
2b- z2a 4.20E+006 2.7 3.7 
2b- z2b 1.08E+007 2.3 2.4 
2e-4b 4.73E+006 2.6 3.6 
2f-2e 2.75E+007 1.9 2.5 
2f- z2 3.48E+006 2.7 2.5 
2f- z2 7.65E+006 2.4 3.7 
3f- x3 3.39E+007 1.9 4.7 
3d-x2 1.40E+007 2.2 7.2 
3f-3b 1.02E+007 2.3 4.3 
3f-3d 9.54E+006 2.3 4.3 
3f- x3 3.94E+006 2.7 2.4 
4b-4f 1.49E+007 2.2 4.3 















4b-2c 1.42E+007 2.2 2.9 
5b- w6 1.10E+007 2.3 4.8 
5b- x5 5.80E+007 1.7 2.3 
5b- x6 2.92E+007 1.9 2.7 
5b- x7 6.41E+006 2.5 3.7 
5b- z6 6.81E+006 2.5 5 
6b-5b 4.31E+006 2.6 4.6 
6b-6c 2.90E+007 1.9 2.5 
6b-x5 6.40E+006 2.5 3.7 
6b-x6 8.40E+006 2.4 2.6 
6b-z6 2.81E+007 1.9 2.5 
6c-4f 9.07E+006 2.3 3.6 
6e-4f 5.31E+006 2.6 3.3 
6f-6e 4.26E+007 1.8 2.5 
6f-OH(z6) 8.86E+006 2.3 3.3 
6f-w6 1.16E+007 2.2 2.8 
6f-z6 3.65E+006 2.7 3.7 
7f-Me 1.51E+007 2.1 3.4 
7f-x7 6.55E+006 2.5 3.6 
w5-4f 1.64E+007 2.1 2.7 
w5-5f 1.15E+007 2.2 2.9 
w5-x4 4.46E+007 1.8 2.3 
w5-x5 8.44E+006 2.4 2.9 
w7-5b 3.64E+007 1.9 2.2 
w7-6b 4.15E+006 2.7 4.1 
w7-7f 4.32E+006 2.6 3.6 
w7-x5 9.98E+006 2.3 3.6 
w7-x6 1.90E+007 2.1 2.3 
w7-x7 1.71E+007 2.1 2.9 
w7-z6 1.63E+007 2.1 3.5 
x2-z2 1.37E+007 2.2 2.4 
x2-z2 8.81E+006 2.4 2.3 
x5-x6 4.00E+007 1.8 2.1 
x7-Me 3.56E+006 2.7 4.2 
z2a-z2b (ref) 4.38E+007 1.8 1.8 
z6-x5 8.88E+006 2.3 4.5 
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The detailed procedure to evaluate the compounds for anti-influenza virus activity in Madin 
Darby canine kidney (MDCK) cells, can be found elswehere.1 In brief, serial dilutions of the 
compounds were added to 96-well plates containing subconfluent cultures of MDCK cells. At 
the same time, influenza virus [A/H1N1 (strain A/PR/8/34 or A/Virginia/ATCC3/2009); 
A/H3N2 (strain A/HK/7/87); or B (strain B/HK/5/72)] was added at a multiplicity of infection 
of 0.0004 plaque-forming units per cell. After 72 h incubation at 35°C, microscopic 
inspection was done to score the virus-induced cytopathic effect (CPE) and calculate the 
compounds’ 50% effective concentration (EC50) values. In parallel, the compounds’ 
cytotoxicity was determined as the minimal cytotoxic concentration (MCC). Then, the 
colorimetric MTS cell viability assay (CellTiter 96® AQueous One Solution Cell Proliferation 
Assay from Promega, Madison, WI, USA) was performed to confirm the 50% antivirally 
effective concentrations and calculate the 50% cytotoxic concentrations (CC50).  
 
Antibacterial study 
The antibacterial activity was tested against a panel of Gram-positive bacteria using broth 




















Figure S1. ESP (Merz–Kollman) charges computed for the B3LYP/6-31G reoptimized lowest-energy GAFF 


















Figure S2. Comparison of some arbitrarily chosen characteristic distances of the a) lowest-energy conformers 
and b) equally weighted average of all low-energy conformers, optimized at GAFF level (r1 = 4d-OH – y6=O , 
r2 = 4d-OH – x1-NH2 , r3 = 4d – x7-COOCH3 , r4 = 4d – 3e-OH , r5 = 4d – 1d-OH , r6 = 6d – 7e-OH , r7 = 6d – 















Figure S3. Comparison of some arbitrarily chosen characteristic distances of all low-energy conformers of the three aglycons optimized at GAFF level, a) 17, b) 1 and c) 14 
(r1 = 4d-OH – y6=O , r2 = 4d-OH – x1-NH2 , r3 = 4d – x7-COOCH3 , r4 = 4d – 3e-OH , r5 = 4d – 1d-OH , r6 = 6d – 7e-OH , r7 = 6d – 7c-OH , r8 = 2d – 7e-OH , r9 = 2d – 

















Figure S4. Experimental solution ECD spectrum (black) of 1 compared with the ZINDO-




Figure S5. Experimental solution ECD spectrum (black) of 17 compared with the ZINDO-

















Figure S6. Experimental solution ECD spectrum (black) of 14 compared with the ZINDO-
calculated ECD spectrum (red) for the 14-F model of the lowest-energy B3LYP/6-31G 
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• Ristocetin and teicoplanin aglycon derivatives were prepared. 
• Their antibacterial and anti-influenza virus activity was measured. 
• The lipophilic side chain was crucial for the antiviral activity 
• The effect of conformation on the antimicrobial activity was studied. 
• Conformation-controlling effect of chloro substituents was identified. 
 
